

# CENTER FOR DRUG EVALUATION AND RESEARCH

**Approval Package for:**

***APPLICATION NUMBER:***

**211527Orig1s000**

***Trade Name:*** AKLIEF®

***Generic or Proper Name:*** trifarotene

***Sponsor:*** Galderma Research and Development, LLC

***Approval Date:*** October 4, 2019

***Indication:*** For the topical treatment of acne vulgaris in patients 9 years of age and older.

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 211527Orig1s000

### CONTENTS

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                                                                                                                                                                                                                                    |          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| <b>Approval Letter</b>                                                                                                                                                                                                                                             | <b>X</b> |
| <b>Other Action Letters</b>                                                                                                                                                                                                                                        |          |
| <b>Labeling</b>                                                                                                                                                                                                                                                    | <b>X</b> |
| <b>REMS</b>                                                                                                                                                                                                                                                        |          |
| <b>Officer/Employee List</b>                                                                                                                                                                                                                                       | <b>X</b> |
| <b>Multidiscipline Review(s)</b> <ul style="list-style-type: none"><li>• Summary Review</li><li>• Office Director</li><li>• Cross Discipline Team Leader</li><li>• Clinical</li><li>• Non-Clinical</li><li>• Statistical</li><li>• Clinical Pharmacology</li></ul> | <b>X</b> |
| <b>Product Quality Review(s)</b>                                                                                                                                                                                                                                   | <b>X</b> |
| <b>Clinical Microbiology / Virology Review(s)</b>                                                                                                                                                                                                                  |          |
| <b>Other Reviews</b>                                                                                                                                                                                                                                               | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b>                                                                                                                                                                                                               | <b>X</b> |
| <b>Proprietary Name Review(s)</b>                                                                                                                                                                                                                                  | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>                                                                                                                                                                                                                   | <b>X</b> |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**211527Orig1s000**

**APPROVAL LETTER**

NDA 211527

## **NDA APPROVAL**

Galderma Research and Development, LLC  
Attention: Bobbi Drais  
Head of Global Regulatory Affairs Development  
14501 North Freeway  
Fort Worth, TX 76177

Dear Ms. Drais:

Please refer to your new drug application (NDA) dated and received October 4, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for AKLIEF® (trifarotene) cream.

This new drug application provides for the use of AKLIEF® (trifarotene) cream for the topical treatment of acne vulgaris in patients 9 years of age and older.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling and carton and container labeling submitted on September 13, 2019, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 211527.**” Approval of this submission by FDA is not required before the labeling is used.

### **ADVISORY COMMITTEE**

Your application for AKLIEF® (trifarotene) cream was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues that were unexpected for a drug of this class.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages birth to 8 years, 11 months, because necessary studies are impossible or highly impracticable. This is because the number of patients in this age group is so small.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the Prescribing Information, Medication Guide, and Patient Package Insert (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup> For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.<sup>6</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

## **MEDWATCH-TO-MANUFACTURER PROGRAM**

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at FDA.gov.<sup>7</sup>

## **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

---

<sup>3</sup> When final, this guidance will represent the FDA's current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

<sup>6</sup> <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>

<sup>7</sup> <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>

If you have any questions, call Dawn Williams, Regulatory Project Manager, at (301)796-5376.

Sincerely,

*{See appended electronic signature page}*

Julie Beitz, MD  
Director  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - o Prescribing Information
  - o Patient Package Insert
- Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

KENDALL A MARCUS  
10/04/2019 07:39:44 AM  
Signing for Dr. Julie Beitz